Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ZEN-3694

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Newsoara Biopharma, Zenith Capital Corp

Drug class:

BET inhibitor

Related drugs:

‹

›

BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3
HER-2 positive	Estrogen Receptor Positive Breast Cancer	HER-2 positive	Estrogen Receptor Positive Breast Cancer	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + ZEN-3694 Sensitive: D – Preclinical palbociclib + ZEN-3694 Sensitive : D	palbociclib + ZEN-3694 Sensitive: D – Preclinical palbociclib + ZEN-3694 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	abemaciclib + ZEN-3694 Sensitive: D – Preclinical abemaciclib + ZEN-3694 Sensitive : D	abemaciclib + ZEN-3694 Sensitive: D – Preclinical abemaciclib + ZEN-3694 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D	ZEN-3694 Sensitive: D – Preclinical ZEN-3694 Sensitive : D